Joint Clinical Trials Office
Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 13, 2025
A prospective, multicenter, single-arm, non-randomized clinical study designed to evaluate the safety and effectiveness of the Citadel Embolization Device
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 24, 2025
Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 27, 2025
A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 27, 2025
A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 26, 2025
Boomerang-Pivotal Multicenter Trial of the Boomerang Catheter for Percutaneous Deep Vein Arterialization (pDVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 31, 2025
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 22, 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Complications
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2025